Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
12.06.23
Pillsbury advised Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd., in a recent closing with Cyprium Therapeutics, a Fortress Biotech, Inc. (Nasdaq: FBIO) subsidiary company.
According to a company press release, Cyprium completed the transfer to Sentynl of worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101, the copper histidinate product candidate for the treatment of Menkes disease, a rare and devastating pediatric disease.
As such, Sentynl will now assume full responsibility for the development and commercialization of CUTX-101. The rolling submission of the CUTX-101 New Drug Application to the FDA is ongoing, with expected completion in 2024.
Click here to read the full company press release.
The Pillsbury deal team included Corporate partner Christian Salaman and associate Kit Ryan.
To learn more about Pillsbury’s previous advisements of Sentynl, including its initial agreement with Cyprium, click here and here.